Other detected homozygous somatic variants included TP53 (c.607G > T p.Val203Leu, VAF 85%, class 3–4) and RB1 (c.2239G > T p.Glu747 *, VAF 85%, class 4–5) During the molecular tumor board meeting both the TSC1 and NF1 variants were considered a potential candidate target rendering sensitivity to mTOR inhibition (Figure 3), even though the initial treatment with everolimus had not, evidently, been successful in this patient. Here, NF1 is linked to neoplasm.